

DOCKET NO.: JJPR-0050 (ORT-1060-CON)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, Michael R. Jackson

and Per A. Peterson

Confirmation No.: 1342

Application No.: 10/785,472

Group Art Unit: 1644

Filing Date: February 23, 2004

Examiner: Francois P. Vandervegt

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

**EXPRESS MAIL LABEL NO: EV670670587US
DATE OF DEPOSIT: October 6, 2005**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☒ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 1 - 2 listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


- ☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.


Please charge any deficiency or credit any overpayment to Deposit Account No.

23-3050. This form is submitted in duplicate.

Date: October 6, 2005


Phillip A. Singer
Registration No. 40,176

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



DOCKET NO.: JJPR-0050 (ORT-1060-CON)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxembourg, Michael R. Jackson,

Per A. Peterson

Confirmation No.: 1342

Application No.: 10/785,472

Group Art Unit: 1644

Filing Date: February 23, 2004

Examiner: Francois P. Vandervegt

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS

**EXPRESS MAIL LABEL NO: EV670670587US
DATE OF DEPOSIT: October 6, 2005**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

- ☐ Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- ☒ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: October 6, 2005


Phillip A. Singer
Registration No. 40,176

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. JJPR-0050 (ORT-0106-CON)	Application No. 10/785,472
		Applicant Alain T. Luxembourg, Michael R. Jackson and Per A. Peterson	
		Filing Date February 23, 2004	Group 1644
		Confirmation No. 1342	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Boog, Claire J. P. et al., "Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells," <i>Eur. J. Immunol.</i> , 19, 1989, 537-542	
	2	Marchal, Ingrid et al., "Glycoproteins from Insect Cells: Sialylated or Not?," <i>Biol. Chem.</i> , 2001, 382, 151-159	
EXAMINER		DATE CONSIDERED	